• Email Us: [email protected]
  • Contact Us: +1 718 618 4351
  • Skip to content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Over 200 Drugs To Get Costlier By Up To 10 Percent In United States As GSK, Pfizer, Others Hike Price

January 7, 2020 by Jennifer Preston Leave a Comment

GlaxoSmithKline, Pfizer, Sanofi, and some other drugmakers have decided prices of around 200 drugs in 2020. The price hike is expected to be up to 10 percent across the board, according to Axis Advisors. GlaxoSmithKline said it will raise prices of drugs like Zejula, Ellipta inhaler, and some other products in its HIV-focused ViiV joint venture. There are a total of 30 drugs manufactured by GlaxoSmithKline that will get costlier. Similarly, Sanofi has decided to raise prices of at least 10 drugs and the hikes will be in the range of 1 percent to 5 percent. The drugmaker said that it won’t raise prices of drugs above medical inflation.

Arthritis medication Xeljanz and cancer medication Ibrance manufactured Pfizer are also expected to expensive by around 5 percent. According to Pfizer spokesperson Amy Rose, over 40 percent of drugs that will see an increase in prices are sterile injectables. Some drugs will see a hike of less than USD 1. Another company on the list is Teva Pharmaceutical Industries Ltd. It has increased prices of over 15 medicines and some of them will be more than 6 percent costlier. A company’s spokesperson said that it is a regular affair to review prices in the context of the cost of production, market conditions, and availability. The entire list of drugs that will get costlier is yet to be released.

The United States has higher drug prices when compared to other countries as it leaves pricing to market competition. This has made it the world’s most lucrative market for drug manufacturers. In several countries, drug prices are directly or indirectly controlled by governments. The hike in drug prices comes just days after the Donald Trump administration proposed a rule to allow the import of cheaper medicines from Canada. Trump, a Republican, has failed to deliver on a promise to lower drug prices before the next presidential election. Earlier in December, the House of Representatives passed a bill that would cap prices of some of the most expensive drugs in the United States based on international prices.

Related posts:

  1. McDonald’s CEO Steps Down After Violating Company Policy
  2. The US President Trump Twitted in Favor to Develop 5G Network In America
  3. The lawsuit filed against the US government by Huawei over new FCC laws
  4. Apple Launches Smart Battery Cases For iPhone 11 Series, Cases Deliver Up To 50 Percent Longer Battery Life

Filed Under: Health

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar


  • Home
  • All Reports
  • About Us
  • Contact Us
  • +1 718 618 4351
  • +91 78878 22626
  • [email protected]
Office Address
Survey No. 51/14 First Floor, Office Number 4, Vishwa Arcade, Near Navale Lawns, Pune, Maharashtra, India 411041

Powered by Prudour Network

Copyrights © 2021 · Medical Market Report. All Rights Reserved.